Present and future pharmacotherapy for heart failure
- 1 July 2002
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 3 (7) , 915-930
Abstract
The pharmacotherapy currently recommended by the American College of Cardiology and the American Heart Association for heart failure (HF) is a diuretic, an angiotensin-converting enzyme inhibitor (ACEI), a β-adrenoceptor antagonist and (usually) digitalis. This current treatment of HF may be improved by optimising the dose of ACEI used, as increasing the dose of lisinopril increases its benefits in HF. Selective angiotensin receptor-1 (AT1) antagonists are effective alternatives for those who cannot tolerate ACEIs. AT1 antagonists may also be used in combination with ACEIs, as some studies have shown cumulative benefits for the combination. In addition to being used in Stage IV HF patients, in whom it has a marked benefit, spironolactone should be studied in less severe HF and in the presence of β-blockers. The use of carvedilol, extended-release metoprolol and bisoprolol should be extended to severe HF patients as these agents have been shown to decrease mortality in this group. The ancillary properties ...Keywords
This publication has 96 references indexed in Scilit:
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- LevosimendanDrugs, 2001
- Neurohormonal activation in severe heart failure: Relations to patient death and the effect of treatment with flosequinanAmerican Heart Journal, 2000
- Dofetilide in Patients with Congestive Heart Failure and Left Ventricular DysfunctionNew England Journal of Medicine, 1999
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 1999
- Combination Diuretic Therapy in Severe Congestive Heart FailureDrugs, 1998
- Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)The Lancet, 1997
- Hemodynamic Effects of a Single Intravenous Injection of Synthetic Human Brain Natriuretic Peptide in Patients With Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy**This study was supported by a grant from Scios Nova, Inc., Mountain View, California.The American Journal of Cardiology, 1996
- Growth Hormone in the Treatment of Dilated CardiomyopathyNew England Journal of Medicine, 1996
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureNew England Journal of Medicine, 1987